Regorafenib, a multitargeted tyrosine kinase inhibitor, proved to be active in patients with soft tissue sarcomas (STS).
Activity of regorafenib in advanced pretreated soft tissue sarcoma: Results of a single-center phase II study
De Sanctis, Rita;Santoro, Armando
2020-01-01
Abstract
Regorafenib, a multitargeted tyrosine kinase inhibitor, proved to be active in patients with soft tissue sarcomas (STS).File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
